Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Known hormone refractory disease~* Multiple skeletal metastases (≥ 2 hot spots) on bone scintigraphy~* No intention to use cytotoxic chemotherapy within the next 6 months~* Either regular (not occasional) analgesic medication use for cancer related bone pain or treatment with EBRT (External Beam Radiation Therapy) for bone pain~Exclusion Criteria:~* Treatment with an investigational drug within previous 4 weeks, or planned during the treatment period~* Eligible for first course of docetaxel, i.e. patients who are fit enough, willing and where docetaxel is available~* Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period, or failure to recover from adverse events due to cytotoxic chemotherapy administered more than 4 weeks ago~* Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within previous 24 weeks~* Other malignancy treated within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)~* History of visceral metastasis, or visceral metastases as assessed by abdominal/pelvic CT or chest x-ray within previous 8 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Xofigo, BAY88-8223) (Type: EXPERIMENTAL): Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).

Based on this trial design, predict the completion outcome and termination type (if applicable).